

Index

- abnormal transcranial Doppler ultrasonography (TCD)
- acetylation, 132–133, 600
- acute chest syndrome, 695
- acute myeloid leukemia, HbA<sub>2</sub>, 127
- acute splenic sequestration, 694
- acute stroke, 694–695. *See also* stroke
- adhesive bridging proteins, sickle red cell adhesion, 144
- adult blood system, HSCs, 3
- AGM. *See* aortagonad-mesonephros
- alkaline Bohr effect, HbF, 120
- allantois, 5, 25–26
- alloimmunization, 700–701
  - sickle cell disease, 700–701
  - thalassemia, 700
- amphibians, 13
- animal models, transgenic mice
  - genetic background, 225
  - HbC impact, 233
  - induced hemoglobinopathies, 232
  - knock-out, knock-in, 225
  - MCHC, 233
  - mouse age, 233
  - sickle cell disease models, 227–232
    - erythrocytes, 229
    - organ pathology, 230–232
      - brain, 232
      - kidney, 230
      - liver, 231
      - lung, 232
      - microcirculation, 230–231
      - pulmonary hypertension, 232
      - retina, 230
      - spleen, 232
    - sickle transgenic mice, 227–229
  - strains, 225
  - technology, 225
  - thalassemic mice, 225–227
  - transgenic expression, 233
- animal research, 3
- antenatal diagnosis, 681–682
- anti-adhesion therapy, sickle cell disease, 759–761
- anti-inflammatory therapy, 762–763
  - sulfasalazine, nuclear factor (NF)-kB, 762
  - targeting ET-1, 762–763
- anti-oxidant therapy targeting erythrocyte, 765–766
  - deferiprone, 765
  - oral glutamine, 765
  - oral N-acetyl-cysteine, 765–766
- anti-oxidant therapy targeting vascular, 763–765
  - Apo A-I mimetics, 764
  - NO, 763–764
  - statins, 764
  - xanthine oxidase inhibitors, 764–765
- anti-thrombotic therapy
  - β-thalassemia, 761–762
  - sickle cell disease, 761–762
- aortagonad-mesonephros (AGM), 6
- Apo A-I mimetics, 764
- apoptosis, vasculature permeability, 193–194
- assays, assay systems, 7, 142
- ATMDS. *See* α thalassemia-myelodysplastic syndromes
- ATR-16 syndrome, 296–304
  - chromosome imbalance, 301–303
  - genetic abnormalities definition, 299–301
  - summary, 303–304
- ATRX syndrome, 304–311
  - associated phenotype, 308
  - ATMDS, 315–316
  - cardiac abnormalities, 305
  - clinical findings, 304–305
  - disease gene identification, 306–307
  - gene, protein product, 307–308
  - head circumference, brain size, 304–305
  - hematologic findings, 305–306
  - mutations, functional consequences, 311
  - neonates, 304
  - normal functional role, 310–311
  - phenotype relationship, 308–309
  - skeletal abnormalities, 305
  - subject behavior, 305
  - summary, 311
  - urogenital abnormalities, 305
  - X-linked condition, 306
- avian, 12–13
  - embryonic hematopoietic hierarchy, 12–13
  - erythroid development, chicken, 12–13
- bacteremia, 649
- basal promoters, 52–53
- BFU-E. *See* burst forming unit-erythroid
- biochemical purification, transcription factors, 63–64
- blood product choice, 692–693
- blood transfusion, HbH disease, 278–279
- BMP-4, 16
- bone disease, 652
- bone marrow transplantation, thalassemia patient
  - effect, 778–780
  - endocrine dysfunction, 780
  - hepatitis, 779–780
  - iron overload, 779
  - mixed chimeric state, 778
  - patient selection, 777–778
  - risk classification, 777–778
  - thalassemia recurrence, 778
  - thalassemia-related complications, 779
  - transplant-related complications, 778–779
- β<sup>S</sup>-linked haplotypes, African/Indo-European, 638–640
- burst forming unit-erythroid (BFU-E), 10, 29
- calcium-activated potassium channel (Gardos pathway), 167–168
- capillary electrophoresis, 660
- capillary IEF, 660
- carbon monoxide poisoning, 613–616
  - clinical features, 615
  - diagnosis, treatment, 615–616
  - epidemiology, 613–614
- cardiac, arterial abnormalities, 151
- cardiac abnormalities, ATRX syndrome, 305
- cardiovascular disease, 652
- cation content, cellular hydration, 164–172
  - calcium-activated potassium channel, 167–168
  - cation permeability alterations, 166–167
  - cell calcium, calcium pump activity, 167
  - cell sodium, 165–167
  - CHC, 164
  - deoxygenation-induced cation leak, 165–167
  - deoxygenation-induced cation permeability, 165–166
  - Gardos channel activity modulation, 168–169
  - KCC, 169–172
    - activation, 172
    - cellular magnesium, 170–171
    - deoxygenation, 170
    - molecular basis, 171–172
  - sodium/hydrogen exchange, 165–167
  - sodium permeability, cell sodium, 167
  - sodium-potassium ATPase, 165–167
  - stress, oxidation, 166–167
- cation permeability alterations, 166–167
- cation transport
  - other hemoglobinopathies, 174
  - thalassemia, 174
- CBC. *See* complete blood count
- CBF transcription, 17
- cell adhesion, erythropoiesis, 34
- cell calcium, calcium pump activity, 167
- cell hemoglobin concentration (CHC), 164
- cell sodium, 165–167
- cellular control, hemoglobin switching, 86–88
  - developmental clock, 87–88
  - models, 86–87
- cellular heterogeneity, HbF, 121–122
- cellular hydration. *See* cation content, cellular hydration
- cellular magnesium, KCC, 170–171
- CFU-C, 9–10
- CFU-E. *See* colony forming units-erythroid
- CFU-S, 10
- CHC. *See* cell hemoglobin concentration
- chelation therapy objectives, 710–721. *See also* iron overload, chelation therapy harmful iron species detoxification, 711 iron balance, 710 safe tissue iron concentrations maintenance, 710–711
- chelator design constraints, 713–714
- ChIP analysis. *See* chromatin immunoprecipitation analysis
- chloride binding, HbF, 120

chorion, 5	effect on heart, 726	myelopoiesis, 8–9
chromatin conformation, EKLF, 38	heart, 726	neonatal repopulating hematopoietic stem cells, 10
chromatin immunoprecipitation (ChIP) analysis, 64–65	pharmacology, 725	T, B lymphoid lineage, mouse populations, 9
chromatin structure remodelling, EKLF, 72	serum ferritin, liver iron, 725	tyrosine c-kit receptor, 8
chromosomal organization, human globin genes, 47–50	treatment safety, 726	epigenetic factors, 17–18
chromosome imbalance, ATR-16 syndrome, 301–303	efficacy, 722–724	PcG proteins, 17
α <sup>0</sup> chromosome, 248–250	heart, 723–724	trxG, 17–18
chronic transfusion therapy indications, 697–699	iron excretion, balance, 722	extraembryonic
other proposed indications, 699	liver iron, 722–723	allantois, 5
pregnancy, 698	neutropenia, agranulocytosis, 724	chorion, 5
pulmonary hypertension, 698–699	recommended dosing, 724	placenta, 5
recurrent acute chest pain, 698–699	serum ferritin, 722	yolk sac, 4–5
recurrent painful episodes, 699	unwanted effects, 724	intraembryonic, PAS/AGM, 5–6
recurrent splenic sequestration, 699	deferoximine, 714–721	mesoderm induction, 3–4
silent cerebral infarcts, 698	chemistry, pharmacology, 715	molecular interactions, 14
stroke, 697	efficacy, 715–717	secondary territories
TCD	heart, 716–717	bone marrow, 6–7
c-kit/SF signalling, 16	historical perspective, 714–715	liver, 6–7
clinical applications, developmental	iron balance, liver iron, 715–716	signalling pathways, 14–16
hematopoiesis, 18	long-term effects on survival, 716	BMP-4, 16
coagulation, spleen, intravascular hemolysis, 209–211	other long-term effects on morbidity, 717	c-kit/SF signalling, 16
CO <sub>2</sub> binding, HbF, 120	serum ferritin, 716	hedgehog signalling, 15
colonization theory, developmental	sickle cell disease, 720–721	TGF-β superfamily, 14–16
hematopoiesis, 3, 6	thalassemia intermedia, 721	VEFG/Flk-1 axis, 16
colony forming units-erythroid (CFU-E), 29	tolerability, 717–719	visceral endoderm contact, 15
common <i>vs.</i> lineage-specific globin gene	auditory toxicity, 718	transcription factors, 16–17
regulation, 51–52	delivery methods, 719–720	CBF, 17
complete blood count (CBC), 664–668	general, 717	GATA-2, 16–17
automated methods, 665	growth, bone, 718	Runx1 haploinsufficiency, 17
cell heterogeneity measures, 666–667	infections, 718	SCL, 16
globin chain synthesis, 667–668	injection site reactions, 717–718	differential phylogenetic footprints, human globin genes, 51
hemoglobin S polymerization, 668	miscellaneous effects, 718–719	distal enhancers, human globin genes, 56–58
manual methods, 664	rinal toxicity, 718	DLP. <i>See</i> dorsal lateral plate
per cent HbS polymer, 668	thalassemia major, 719–720	DNA diagnosis, 669–682
rate of sickling, 668	rescue therapy, 719	abnormal hemoglobins, 679–681
reticulocyte count, 665–666	standard therapy, 719	HbC, 679
compound phenotypes, integrated measures, 651	deoxygenation, KCC, 170	HbE, 679
cooperative binding, 101	deoxygenation-induced cation leak, 165–167	Hb O-Arab, 679
CpG islands, human globin genes, 50	deoxygenation-induced cation permeability, 165–166	HbS, 679
Cre-ERT. <i>See</i> Cre recombinase	developmental abnormalities, 296	other variants, 679–681
Cre-lox recombination system, 13	developmental hematopoiesis, 3–7	Hb Lepore, 679
Cre recombinase (Cre-ERT), 14	animal research, 3	HPFH, 679
cutaneous leg ulceration, 212	clinical application, 18	preimplantation diagnosis, 670–671
β-93 cysteine, sickle cell hemoglobin (HbS), 110	colonization theory, 3, 6	α thalassemia, 671–673
cytochrome b5 deficiency, 608–610	current research, 3	deletion mutations by PCR diagnosis, 671–672
	developmental subsets, 14	diagnostic strategy, 671
	embryonic hematopoietic hierarchy, 3, 7–14	point mutations by PCR diagnosis, 672–673
	amphibians, 13	β thalassemia, 673–679
	assays, 7	allele-specific oligonucleotide PCR, 673–674
	avian, 12–13	β-globin gene haplotype analysis, 678–679
	Cre-ERT, 14	diagnostic strategy, 673
	Cre-lox recombination system, 13	gap-PCR, MLPA analysis, 677
	erythroid-myeloid-lymphoid multipotential progenitors, 10	oligonucleotide microarrays, 674
	erythroid-myeloid progenitors	PCR methods, unknown mutations, 677–678
	BFU-E, 10	point mutations, other methods, 677
	CFU-C, 9–10	primer-specific amplification, 674–675
	CFU-S, 10	restriction enzyme PCR, 675–677
	erythropoiesis, 8	δβ-thalassemia, 679
	hematopoietic colonization, migration, 12	DNA sources, 669–671
	hematopoietic lineages, direct precursors, 11	amniotic fluid, 669–670
	HSCs, 10	blood, 669
	β1 integrin, 13	chorionic villi, 670
	lymphopoiesis, 9	fetal cells in maternal blood, 670
	mammals, 13–14	fetal DNA in maternal plasma, 670
	model, 11–12	dorsal lateral plate (DLP), 25

- double nucleation theory, HbS, 111
  - dyshemoglobinemias. *See* carbon monoxide poisoning; methemoglobinemia; sulfhemoglobinemia
  - EKLF, 37–38, 72–73
    - chromatin structure remodelling, 72
    - post translational modifications, 72
  - EKLF, CACCC box-binding proteins, 70–73
    - $\beta$ -globin gene expression, 70–71
    - $\beta$ -globin switching, 71
  - electrophoresis, 658–659
  - elevated HbF, medical conditions, 122–123
  - embryonic hematopoietic hierarchy, 3, 7–14
    - amphibians, 13
      - assays, 7
      - avian, 12–13
      - $\beta$ 1 integrin, 13
      - Cre-ERT, 14
      - Cre-lox recombination system, 13
    - erythroid-myeloid-lymphoid multipotential progenitors, 10
    - erythroid-myeloid progenitors
      - BFU-E, 10
      - CFU-C, 9–10
      - CFU-S, 10
    - erythropoiesis, 8
    - hematopoietic colonization, migration, 12
    - hematopoietic lineages, direct precursors, 11
    - hematopoietic stem cells, 10
    - lymphopoiesis, 9
    - mammals, 13–14
    - model, 11–12
    - myeloipoiesis, 8–9
    - neonatal repopulating hematopoietic stem cells, 10
    - T, B lymphoid lineage, mouse populations, 9
    - tyrosine c-kit receptor, 8
  - embryonic hemoglobins, thalassemias, hemoglobinopathies, 130
  - EMP. *See* erythroblast-microphage protein
  - endothelial activation, sickle cell disease, 141–142
  - endothelial adhesion molecules, sickle red cell adhesion, 144–146
  - endothelial cell proliferation, angiogenesis, vasculature permeability, NO, 193
  - endothelial response, sickle red cell adhesion, 146
  - epigenetic factors, developmental hematopoiesis, 17–18
    - PcG proteins, 17
    - trxG, 17–18
  - episodic transfusions, indications, 694–697
  - epistatic interactions between protective polymorphisms, 631
  - EpoR, cell-signalling, 31–32
  - erythroblastic islands, 33–34
  - erythroblast-microphage protein (EMP), 29
  - erythrocyte dehydration inhibitors, 757–759
    - $\beta$ -thalassemia, 759
    - Gardos channel, 757–758
    - K-C1 transport inhibition by magnesium, 758–759
    - sickle cell disease, 757
  - erythrocyte membrane
    - ISCs, 161
    - membrane lipids, 161–164
      - membrane lipid alterations, 162
      - phosphoinositides, 163–164
      - phospholipid asymmetry loss, 162–163
      - phospholipid asymmetry maintenance, 162
    - membrane loss, vesiculation, 161
    - membrane pathobiology, 158–159
      - membrane-associated iron, 159
      - oxidant stress, 158–159
    - membrane skeleton, 159–161
    - structure, function, 158
  - erythrocyte proteins and lipids, 202–203
  - erythroid cell purification, 30
  - erythroid cells, liquid culture, 29–30
  - erythroid differentiation, 26–28
    - tissue culture models, 64
  - erythroid maturation, gene expression, 38–39
  - erythroid-myeloid-lymphoid multipotential progenitors, 10
  - erythroid progenitors, 29
    - BFU-E, 10, 29
    - CFU-C, 9–10
    - CFU-E, 29
    - CFU-S, 10
  - erythroid transcription factors
    - EKLF, 72–73
      - chromatin structure remodelling, 72
      - post translational modifications, 72
    - EKLF, CACCC box-binding proteins, 70–73
      - $\beta$ -globin gene expression, 70–71
      - $\beta$ -globin switching, 71
    - GATA-1, related proteins, 67–70
    - GATA-1 interacting proteins, 68–69
    - GATA protein family, 67
    - human disease, 69–70, 75
    - post translational modifications, 68
    - structure-function analysis, 68
    - terminal erythroid maturation, platelet formation, 67
    - transcription repression, 68
  - general principles, 62–63
  - NF-E2, related proteins, 73–74
    - action mechanisms, 74
    - Maf family, 73–74
    - MARE elements, 73–74
    - p45 family, 73
  - SCL, 70
- erythroleukemia, HbA<sub>2</sub>, clinical aspects, 127
- erythropoiesis, 8
  - allantois, 25–26
  - cell adhesion, 34
  - chicken, 25–26
  - chromatin conformation, EKLF, 38
  - during development, 24
  - EKLF transcription factor, 37–38
  - EMP, 29
  - Epo, 30–31
  - EpoR, cell-signalling, 31–32
  - erythroblastic islands, 33–34
  - erythroid cell purification, 30
  - erythroid cells, liquid culture, 29–30
  - erythroid differentiation, 26–28
  - erythroid maturation, gene expression, 38–39
  - erythroid progenitors, 29
    - BFU-E, 29
    - CFU-E, 29
  - GATA-1, 34, 36–37
  - hereditary anemias, 34
  - hormonal influences, other, 33
  - hypoxia sensing, 30
  - hypoxia stress, 34
  - ineffective erythropoiesis and, 34
  - macrophage-erythroblast attacher MAEA, 29
  - mammalian, 26
    - hemoglobin tetramers, 26
    - HPFH, 26
    - primitive cells, embryonic globins expression, 26
  - paladin, 34
  - primitive, 24–25
  - REDS signalling, 34
  - regulation, 30
  - signal transduction molecules, knockout phenotypes, 32–33
  - steady state, 33
  - stress erythropoiesis, 34–35
  - transcription regulation, 35–36
  - turn over, production rates, 24
- erythropoiesis, *Xenopus laevis*, 25
  - DLP, 25
  - VBIs, 25
- erythropoiesis, Zebrafish (*Danio rerio*), 24–25
  - Epo production, 25
  - morpholinos, morphants, 24
  - sites, anatomical location, 25
- erythropoietin (Epo), 25, 30–31
- ET-1. *See* targeting endothelin-1
- ethical and counseling issues, 634–635
- exceptionally high HbA<sub>2</sub>, 128
- excess iron distribution, 703–704
- exchange transfusion, 693
- expression regulation, polymorphisms, trans-acting regulatory elements, 642
- extracellular (EC) matrix adhesion molecules, sickle red cell adhesion, sickle cell disease, 146
- extraembryonic factors, developmental hematopoiesis
  - allantois, 5
  - chorion, 5
  - placenta, 5
  - yolk sac, 4–5
- facial appearance, ATRX syndrome, 305
- F cells, HbF, 121–122
- fetal cells, HbF, 121
- fetal hemoglobin (HbF) induction
  - background, 745
  - clinical efficacy, 751
  - combination therapy, 751–752
  - DNA hypomethylating agents, 745–748
  - histone deacetylases, inhibitors, 750
  - hydroxyurea, 748–750
    - action mechanisms, 749–750
    - children, 748
    - clinical use, 748–749
    - response to treatment prediction, 749
- fetal hemoglobin synthesis, pharmacological induction, 93–94
- foamy virus vectors, 798
- F-reticulocytes, HbF, 122
- Gardos channel, 167–169, 757–758
- gastro-intestinal abnormalities, ATRX syndrome, 305

GATA-1, related proteins, 34, 36, 67, 70	compound phenotypes, integrated measures, 651	$\beta$ -globin switching, EKLF, CACCC box-binding proteins, 71
GATA protein family, 67	genetic polymorphisms, disease severity predictors, 645–651	$\delta$ -globin chain synthesis, HbA <sub>2</sub> , 124–125
human disease, 69–70, 75	G-6-PD deficiency, 650–651	$\delta$ -globin gene
interacting proteins, 68–69	hyperbilirubinemia, gallstones, 650	$\delta$ -globin, 124–126
mutations, 36–37	leg ulcers, 649	in vitro transcription, 125
post translational modifications, 68	osteonecrosis, 649	$\delta$ -globin gene evolution, HbA <sub>2</sub> , 124
structure-function analysis, 68	painful episodes, 646	$\delta$ -globin gene mutations, HbA <sub>2</sub> ,
terminal erythroid maturation, platelet formation, 67	priapism, 649	$\epsilon$ -globin gene, regulatory elements, 88–89
transcription repression, 68	pulmonary disease, 649–650	globin gene locus regulatory elements, 801
GATA-2 transcription, 16–17	renal disease, 649	globin gene splicing, 90–91
G+C content, human globin genes, 50–51	stroke, 646–649	globin gene structure, introns, human globin genes, 46–47
gene competition, molecular control, 92	$\alpha$ thalassemia,	$\gamma$ -globin genes
gene mutation, $\gamma$ -globin genes, 123–124	$\beta$ thalassemia, 644–645	$\gamma$ -globin structure, HbF, 119
gene therapy	sickle cell disease,	lentiviral vectors, 803–804
foamy virus vectors, 798	$\beta$ thalassemia, 640–641, 651–652	regulatory elements, 89
future prospects, 807	alpha-hemoglobin stabilizing protein role, 644–645	globin lentiviral vectors, 801
gene transfer into hematopoietic stem cells (HSCs), 798–799	bone disease, 652	globin retroviral vector, 801
$\beta$ -globin lentiviral vectors, murine model correction, 802–803	cardiovascular disease, 652	globin synthesis ratios, $\alpha$ thalassemia, 266–267
globin gene locus regulatory elements, 801	genetic polymorphisms, disease severity predictors, 651–652	G-6-PD deficiency, 650–651
$\gamma$ -globin lentiviral vectors, 803–804	hyperbilirubinemia, gallstones, 651	growth, bone changes, HbH disease, 279
globin lentiviral vectors, 801	iron loading, 651–652	
globin retroviral vector, 801	genetic polymorphisms, disease severity predictors, 645–652	haptoglobin, hemolysis, sickle cell disease and thalassemia, 204
HfV, 798	genetic services in developing countries, 635	HbA <sub>2</sub> , 662
human $\beta$ -thalassemia erythroid cells correction, 804	gene transfer into hematopoietic stem cells (HSCs), 798–799	HbA <sub>2</sub> , Lepore hemoglobins, 125
human HSC transduction	G $\gamma$ gene 5' regulatory region, 642	HbA <sub>2</sub> ' (HbB <sub>2</sub> ), 125–126
biological obstacles, 799	$\alpha$ -	HbA <sub>2</sub> level, developmental changes, 126
enrichment, in vivo selection strategies, 800–801	$\beta$ -globins, genomic context, 50–51	HbAS, 629
multiplicity of infection (MOI), 800	$\beta$ -like globins, 46–47	Hb Bart's hydrops fetalis syndrome, 282
new approaches, 799–800	$\alpha/\beta$ globin mRNA, $\alpha$ thalassemia, 266–267	clinical, autopsy findings, 283
vector titer, 800	$\alpha$ globin cluster	HbH hydrops fetalis, 284–285
immunodeficiency disorders, 804–805	$\alpha^+$ chromosomes expression, 248–250	hemoglobin composition, developmental changes, 282–283
insertional mutagenesis, 805–807	normal structure, 241	long term survival, 285–286
lentiviral vectors, 795–798	$\alpha^0$ thalassemia, 248–250	maternal complications, 283–284
murine retroviral vectors, 792–795	protein products, 241–243	mRNA, globin synthesis, 282
positioning effects, globin vector expression, 804	transcription, 241	causes, 281
progress, problems, 804–807	variants	$\alpha^0$ thalassemia defects, 281–282
SCD, mouse models, 801–802	non-thalassemia causing, 243–246	severe fetal anemia, 282
$\beta$ thalassemia, mouse models, 801–802	chromosomal rearrangements, 243–244	prevention, management, 285–286
viral vectors,	deletions and insertions, $\alpha$ -complex, 245	red cell indices, hematologic findings, 282
genetic counselling	gene conversion, 245	HBB enhancer, 55
HbH disease, 281	globin genes variation, 244–245	Hb Beth Bologna, 593
$\alpha$ thalassemia, 273–274	16p telomere, 244	Hb Beth Israel, 593
genetic modulation	restriction site polymorphisms, 245–246	Hb Bruxelles, 593
$\beta^S$ -linked haplotypes molecular characteristics, African and Indo-European, 638–640	variable number tandem of repeats (VNTRs), 246	HbC, 629, 679
$\beta$ -globin gene cluster haplotype on HbF effects, 640–641	$\alpha$ thalassemia causing, 246–248	HbC impact, animal models, 233
$\beta$ -globin ( <i>HBB</i> ) gene-like cluster, 638–640	$\alpha$ globin structural variants interaction, $\alpha$ thalassemia, 286–287	Hb Constant Spring mutation, $\alpha$ thalassemia, 275–276
HbF, 638, 641, 644	$\beta$ -globin gene	Hb Costa Rica, 601
$\beta$ -globin gene silencer, 641–642	EKLF, CACCC box-binding proteins, 70–71	HbE, 629–630, 679
expression regulation, polymorphisms in trans-acting regulatory elements, 642	haplotype on HbF effects, 640–641	HbF, 638, 641, 644, 661–662
G $\gamma$ gene 5' regulatory region, 642	regulatory elements, 89–90	$\beta$ cluster sequence differences, 348
LCR and HbF, 641	silencer, 641–642	$\beta$ -globin gene silencer, 641–642
sickle cell disease phenotype, $\beta$ -globin gene cluster haplotype effects, 643–644	$\beta$ -globin gene-like cluster, 638–640	$\delta\beta$ thalassemia and HPFH deletions, 344–345
HbH disease, 652	$\beta$ -globin gene silencer, 641–642	G $\gamma$ A $\gamma$ and $\delta\beta$ competition, 344
hemoglobin A <sub>2</sub> , 645	$\beta$ -globin lentiviral vectors, murine model correction, 802–803	newly apposed enhancer sequences, 344–345
sickle cell anemia, 645	$\beta$ -globin locus control region (LCR), 90	regulatory regions loss, 344
bacteremia, 649	$\beta$ globin structural variants interaction, $\alpha$ thalassemia, 287–288	expression regulation, polymorphisms in trans-acting regulatory elements, 642

HbF-containing erythrocytes, physiology, 120	β thalassemia, 774–775	hemoglobin modifiers, 755–757
HbF control, adult, 92–93	first cases, 774	β-thalassemia, 756–757
HbF levels modulation, 120–121	Pesaro experience, 774–775	sickle cell disease, 755–756
HbF-Sardinia, HbF, 124	donor cells, alternate sources, 786–787	hemoglobinopathies, clinical evaluation, 668–669
HBG1 enhancer, human globin genes, 55	HLA-nonidentical related donor transplant, 777	hemoglobin-oxygen affinity, tissue oxygen levels, NO, 189–190
HbG-Philadelphia, 601–602	matched unrelated donors, 777	hemoglobin Porto Alegre, 602
HbH disease, 276, 652	other transplant centers, 776	hemoglobins
blood transfusion, 278–279	sickle cell disease, 780–787	abnormal, 679–681
clinical features, 278–280	current results, 780–784	HbC, 679
blood transfusion, 278–279	donor hematopoiesis effect, sickle vasocclusion, 784	HbE, 679
growth, bone changes, 279	growth, development after, 785–786	Hb O-Arab, 679
hepatosplenomegaly, jaundice, 279	non-myeloablative, 783–784	HbS, 679
iron status, 279–280	stable donor-host chimerism, 782–783	other variants, 679–681
pregnancy, 279	thalassemia patient, bone marrow transplantation, 777–778	hyperunstable, 597
presentation, 278	effect, 778–780	unstable, 593–597
rare complications, 280	endocrine dysfunction, 780	clinical aspects, 596–597
severe anemia episodes, 278	hepatitis, 779–780	Hb Köln, 597
deletional, non-deletional, 277	iron overload, 779	Hb Zürich, 597
genetic counselling, 281	mixed chimeric state, 778	miscellaneous, 597
genotype, 277	patient selection, 777–778	diagnosis, 596
phenotype relationship, 280	risk classification, 777–778	blood smear, Heinz body preparation, 596
geographic distribution, 276	thalassemia recurrence, 778	hemoglobin stability tests, 596
α/β globin mRNA, 277	thalassemia-related complications, 779	mutation analysis, 596
globin synthesis ratios, 277	transplant-related complications, 778–779	variant hemoglobin detection, 596
growth, bone changes, 279	hemoglobin	hyperunstable, 597
hematologic findings, 277	functional properties, 662–663	pathophysiology, 594–596
hemoglobin analysis, 277–278	normal function, 101–105	treatment, 597
hepatosplenomegaly, jaundice, 279	cooperative binding, 101	hemoglobin switching, 121
iron status, 279–280	methemoglobin, 105	cellular control, 86–88
pathophysiology, 276–277	MWC/Perutz model, 102–104	developmental clock, 87–88
patient treatment, 280–281	oxygen transport, 101–104	models, 86–87
blood transfusion, 280	transport, other gases, 104–105	developmental, 86
complications, 281	structural aspects, 101	fetal hemoglobin synthesis, pharmacological induction, 93–94
splenectomy, 280	hemoglobin A <sub>2</sub> , 645	HbF, 121
pregnancy, 279	hemoglobin A <sub>2</sub> (HbA <sub>2</sub> ), 124–129	molecular control, 88–90, 93
presentation, 278	African Americans, 125–126	β-globin gene, regulatory elements, 89–90
rare complications, 280	δ-globin chain synthesis, 124–125	β-globin locus control region (LCR), 90
red cell indices, 277	δ-globin gene	ε-globin gene, regulatory elements, 88–89
severe anemia episodes, 278	δ-globin, 124–126	gene competition, 92
HbH hydrops fetalis, 284–285	in vitro transcription, 125	γ-globin gene, regulatory elements, 89
HbI, 602–603	δ-globin gene evolution, 124	globin gene splicing, 90–91
Hb Kenya, 341–342	δ-globin gene mutations, 125–126	HbF control, adult, 92–93
Hb Lepore, 341–343, 679	functional aspects, 125	short chain fatty acids, 93–94
Hb O-Arab, 679	Lepore hemoglobins, 125	hemoglobins with altered oxygen affinity, 590–593
Hb Raleigh, 600	hemoglobin composition, developmental changes, Hb Bart's hydrops fetalis syndrome, 282–283	high oxygen affinity variants, 590–592
HbS, 629, 679	hemoglobin disorders distribution, 625–626	β-globin chain variants, 591–592
HbS co-polymerization, 110–111	hemoglobin disorders frequency, 625–626	diagnosis, 590–591
Hb Setif pseudosickling, hemoglobin oligomerization, 602	hemoglobin F (HbF), 119–124	α-globin chain variants, 591
HbS higher order aggregation, 106–108	cellular heterogeneity, 121–122	low oxygen affinity variants, 592–593
HbS polymer, 105–106	elevated HbF, medical conditions, 122–123	clinical features, 593
HbS polymerization, red blood cells, 113	F cells, 121–122	diagnosis, 592–593
HbS polymer melting, 112–113	fetal cells, 121	Hb Beth Bologna, 593
HbS polymer rheology, 108	F-reticulocytes, 122	Hb Beth Israel, 593
HbS thermodynamics, 108–109	functional properties, 119–120	Hb Bruxelles, 593
hedgehog signalling, 15	gene mutation, γ-globin genes, 122–123	pathophysiology, 592
hematologic phenotype, β globin variants, α thalassemia, 288	γ-globin genes, γ-globin structure, 119	hemoglobin Vicksburg, 601
hematopoietic colonization, migration, 12	HbF-containing erythrocytes physiology, 120	hemolysis, sickle cell disease and thalassemia, 201–204
hematopoietic lineages, direct precursors, 11	hemoglobin switching, 120–121	adherent immunoglobulin G (IgG), 204
hematopoietic stem cells (HSCs), 10	laboratory detection, 122	complement-mediated, 204
adult blood system, 3	protein conformation, 119	extravascular, clinical consequences, 204
hematopoietic stem cell transplantation	hemoglobin G Coughatta, 600–601	extravascular <i>vs.</i> intravascular, 201
alternative donors, 776–777		haptoglobin, 204
alternative sources, 776–780		hemoglobin clearance, 204–206
reduced intensity implants, 776		



- hemolysis, sickle cell disease (*cont.*)
    - hemolytic anemia-associated clinical subphenotypes, 211–215
    - cutaneous leg ulceration, 212
    - priapism, 211–212
    - pulmonary hypertension, 211–213
      - children, 214–215
      - diagnosis, 215–216
      - patient prognosis, 213
      - treatment, 215–216
    - stroke, 212
  - hemopexin, 204–205
  - intravascular, clinical consequences, 206–211
    - coagulation, spleen, 209–211
    - NO resistance, 206–209
    - NOS substrate bioavailability, arginaseemia limitations, 209
  - ISCs, 201
    - mechanical fragility, 203–204
    - shear stress, 203–204
  - oxidation of erythrocyte proteins, lipids, 202–203
  - hemopexin, 204–205
  - hepatosplenomegaly, jaundice, 279
  - hereditary anemias, 34
  - hereditary methemoglobinemia
  - Hereditary Persistence of Fetal Hemoglobin (HPFH), 26, 679
    - deletional, 341
    - human globin genes, 50
    - unlinked to  $\beta$  globin cluster, 341
      - chromosome 2 linked, 348
      - chromosome 6 linked, 347–348
      - chromosome 8 linked, 348
    - X-linked, 347
  - heterogeneous nucleation, HbS
  - HFV. *See* human foamy virus
  - high HbA<sub>2</sub>, 127–129
  - homogeneous nucleation, HbS, 111–112
  - homozygotes,  $\beta$  chain abnormalities,  $\alpha$  thalassemia, 288–289
  - hormonal influences, erythropoiesis, 33
  - HPFH. *See* Hereditary Persistence of Fetal Hemoglobin
  - HPFH and  $\delta\beta$  thalassemia, 338–341
    - classification, 338–340
    - deletion mechanisms, 344
    - deletions, 340
    - intracellular HbF distribution, 343–344
  - HPLC, 660
  - HSCs. *See* hematopoietic stem cells
  - human  $\beta$ -thalassemia erythroid cells correction, 804
  - human foamy virus (HFV), 798
  - human globin genes
    - chromosomal organization, detailed, 47–50
    - CpG islands, 50
    - evolutionary insights, 51–58
      - basal promoters, 52–53
      - common *vs.* lineage-specific regulation, 51–52
    - differential phylogenetic footprints, 51
    - distal enhancers, 56–58
    - HBB enhancer, 55
    - HBG1 enhancer, 55
    - motivation, 51
    - phastCons score, 52
    - phylogenetic footprints, 51
    - proximal enhancers, 55–56
    - RP score, 52
    - sequence alignments, quantitative analysis, 52
    - tissue, developmental specificity
    - upstream regulatory sequences, 53–55
  - G+C content, 50–51
  - globin gene structure, introns, 46–47
  - $\alpha$ -,  $\beta$ - globins, genomic context, 50–51
  - $\alpha$ -,  $\beta$ -like globins, 46–47
  - HPFH, 50
  - introns, 46–47
  - number, chromosomal localization, 46–47
  - pseudogenes, 48
  - splicing, 47
- human HSC transduction
    - biological obstacles, 799
    - enrichment, in vivo selection strategies, 800–801
  - MOI, 800
  - new approaches, 799–800
  - vector titer, 800
- hydroxyurea
    - HbF induction, 748–750
      - action mechanisms, 749–750
      - children, 748
      - clinical use, 748–749
      - response to treatment prediction, 749
    - sickle red cell adhesion, 146
  - hyperbilirubinemia, gallstones, 650–651
  - hypercoagulation
    - sickle cell disease, 150
    - thalassemia, 151
  - hypersplenism, 701–702
  - hyperunstable hemoglobins, 597
  - hypoxia sensing, erythropoiesis, 30
  - hypoxia stress, erythropoiesis, 34
  - hypoxic vasodilation, NO, 190–191
- immunodeficiency disorders, 804–805
  - induced hemoglobinopathies, animal models, 232
  - ineffective erythropoiesis, 34
  - insertional mutagenesis, 805–807
  - $\beta$ 1 integrin, 13
  - interesting  $\alpha$ -globin gene variants, with point mutations
    - HbG-Philadelphia, 601–602
    - HbI, 602–603
    - Hb Setif pseudosickling, hemoglobin oligomerization, 602
    - hemoglobin Porto Alegre, 602
  - interesting  $\beta$ -globin gene variants, with point mutations, 600–601
    - Hb Costa Rica, 601
    - hemoglobin G Coushatta, 600–601
    - hemoglobin Vicksburg, 601
  - intraembryonic factors, developmental hematopoiesis, PAS/AGM, 5–6
  - intravascular hemolysis, clinical consequences, 206–211
    - coagulation, spleen, 209–211
    - NO resistance, 206–209
    - NOS substrate bioavailability, arginaseemia limitations, 209
  - introns, 46–47
  - iron deficiency, HbA<sub>2</sub>, clinical aspects, 126–127
  - iron loading, 651–652
  - iron overload, chelation therapy, 702–729
    - chelating therapy objectives, 710–721
      - harmful iron species detoxification, 711
    - iron balance, 710
    - safe tissue iron concentrations maintenance, 710–711
  - chelator design constraints, 713–714
  - consequences, 704–706
  - deferoximine, 714–721
    - chemistry, pharmacology, 715
    - efficacy, 715–717
    - heart, 716–717
    - historical perspective, 714–715
    - iron balance, liver iron, 715–716
    - long-term effects on survival, 716
    - other long-term effects on morbidity, 717
    - serum ferritin, 716
  - sickle cell disease, 720–721
  - thalassemia intermedia, 721
  - tolerability, 717–719
    - auditory toxicity, 718
    - delivery methods, 719–720
    - general, 717
    - growth, bone, 718
    - infections, 718
    - injection site reactions, 717–718
    - miscellaneous effects, 718–719
    - renal toxicity, 718
    - thalassemia major, 719–720
    - thalassemia major, rescue therapy, 719
    - thalassemia major, standard therapy, 719
- excess iron distribution, 703–704
  - future perspectives, 729
  - iron loading rates, 702–703
  - iron overload monitoring, 707–710
    - clinical effects iron overload, 709
    - heart, 708–709
    - liver iron concentration, 707–708
    - other markers, 710
    - serum ferritin use, limitations, 708
    - tissue iron monitoring, other organ, 709
    - urine iron excretion, 709–710
  - iron overload pathophysiology, 702–703
  - iron overload toxicity mechanisms, 704–705
  - iron pools available for chelation, 711–713
    - extracellular iron, 711–712
    - intracellular iron, 712–713
  - oral chelation therapy, 721–729
    - deferasirox, unwanted effects/management, 727–729
      - children, 728
      - gastrointestinal disturbances, 728
      - liver function, 728
      - other effects, 728
      - recommended dosing regimen, 728–729
      - renal effects, 728
      - skin rash, 728
    - deferasirox (ICL670, Exjade), 726–727
      - chemistry, pharmacology, 726–727
      - effects on heart, 727
      - effects on iron balance, LIC, ferritin, 727
      - historical perspective, 726
    - deferiprone, 721–724
      - chemistry, pharmacology, 721–722
    - deferoximine, 725–726
    - deferoximine, clinical regimes assisted, 725

deferoximine, effect on heart, 726	HbS, 679	lentiviral vectors, 795–798
deferoximine, effect on serum ferritin and liver iron, 725	other variants, 679–681	leukocyte adhesion, vasculature permeability, 195–196
deferoximine, heart, 726	β thalassemia, 673–679	leukocytes, vasoocclusion, 147
deferoximine, pharmacology, 725	allele-specific oligonucleotide PCR, 673–674	LIC. <i>See</i> liver iron concentration
deferoximine, serum ferritin and liver iron, 725	β-globin gene haplotype analysis, 678–679	liver iron concentration (LIC), 707–708
deferoximine, treatment safety, 726	diagnostic strategy, 673	low HbA <sub>2</sub> , 126
efficacy, 722–724	gap-PCR, MLPA analysis, 677	lymphopoiesis, 9
heart, 723–724	oligonucleotide microarrays, 674	
iron excretion, balance, 722	PCR methods, unknown mutations, 677–678	macrophage-erythroblast attacher, 29
liver iron, 722–723	point mutations, other methods, 677	Maf family, NF-E2, related proteins, 73–74
neutropenia, agranulocytosis, 724	primer-specific amplification, 674–675	malaria, HbA <sub>2</sub> , 129
recommended dosing, 724	restriction enzyme PCR, 675–677	malaria hypothesis, 626–629, 632
serum ferritin, 722		mammals, 13–14
unwanted effects, 724	δβ-thalassemia, 679	MARE elements, NF-E2, related proteins, 73–74
other transfusion dependent anemias, 706–707	Hb Lepore, 679	maternal complications, Hb Bart’s hydrops fetalis syndrome, 283–284
sickle cell disease, 706	HPFH, 679	MDS. <i>See</i> myelodysplastic syndromes
thalassemia, 704–706	preimplantation diagnosis, 670–671	megaloblastic anemias, HbA <sub>2</sub> , 129
thalassemia major, 705–706	α thalassemia, 671–673	membrane-associated iron, 159
iron overload monitoring, 707–710	deletion mutations by PCR diagnosis, 671–672	membrane lipids, 161–164
clinical effects iron overload, 709	diagnostic strategy, 671	alterations, 162
heart, 708–709	point mutations by PCR diagnosis, 672–673	membrane lipid alterations, 162
other markers, 710	DNA sources, 669–671	phosphoinositides, 163–164
serum ferritin use, limitations, 708	amniotic fluid, 669–670	phospholipid asymmetry loss, 162–163
tissue iron monitoring, other organ, 709	blood, 669	phospholipid asymmetry maintenance, 162
urine iron excretion, 709–710	chorionic villi, 670	membrane loss, vesiculation, 161
iron overload toxicity mechanisms, 704–705	fetal cells in maternal blood, 670	membrane pathobiology, 158–159
iron pools available for chelation, 711–713	fetal DNA in maternal plasma, 670	membrane-associated iron, 159
extracellular iron, 711–712	protein and cellular based methods, 658–664	oxidant stress, 158–159
intracellular iron, 712–713	capillary electrophoresis, 660	membrane skeleton, 159–161
iron status, HbH disease, 279–280	capillary IEF, 660	mental retardation, ATR-16 syndrome, 296
irreversibly sickled cells (ISCs), 161	electrophoresis, 658–659	mesoderm induction, developmental hematopoiesis, 3–4
hemolysis, sickle cell disease and thalassemia, 201	HbA <sub>2</sub> , 662	methemoglobin, 105
mechanical fragility, hemolysis, sickle cell disease and thalassemia, 203–204	HbF, 661–662	methemoglobinemia, 607–613
shear stress, hemolysis, sickle cell disease and thalassemia, 203–204	hemoglobin, functional properties, 662–663	acquired, 610–611
ISC. <i>See</i> irreversibly sickled cells	hemoglobinopathies, clinical evaluation, 668–669	clinical features, 611
isoelectric focusing (IEF), 659–660	HPLC, 660	diagnosis, 611–612
IVSs. <i>See</i> intervening sequences	isoelectric focusing (IEF), 659–660	hereditary, 608–610
	mass spectrometry, 660–661	cytochrome b5 deficiency, 610
jaundice, HbH disease, 279	oxygen saturation measurements, P <sub>50</sub> , 662–663	cytochrome b5 reductase deficiency, 608–609
juvenile chronic granulocytic leukemia, HbA <sub>2</sub> , clinical aspects, 127	red cell polymer formation detection, solutions containing HbS, 663–664	type I cytochrome b5 reductase deficiency, 609
	C <sub>SAT</sub> , 663–664	type II cytochrome b5 reductase deficiency, 609–610
KCC. <i>See</i> KC1 cotransport	plasma hemoglobin, 664	methemoglobin production, 607
KC1 cotransport (KCC), 169–172	solubility, 663	methemoglobin reduction, 607–608
activation, 172	sample preservation, preparation, laboratory safety, 658	pathophysiology, 607–608
cellular magnesium, 170–171	thalassemias, clinical evaluation, 668–669	treatment, 612–613
deoxygenation, 170	red blood cell characterization, 664–669	acquired methemoglobinemia, 613
molecular basis, 171–172	complete blood count (CBC), 664–668	hereditary methemoglobinemia
KC-1 transport, inhibition by magnesium, 758–759	automated methods, 665	methemoglobin production, 607
knock-out/knock-in animal models, 225	cell heterogeneity measures, 666–667	methemoglobin reduction, 607–608
Krüppel-like transcription factor. <i>See</i> EKLf transcription factor	globin chain synthesis, 667–668	microarray analysis, transcription factors, 64–65
	hemoglobin S polymerization, 668	mild hemolytic anaemia, α thalassemia, 275–276
laboratory methods	manual methods, 664	minor hemoglobins, post-translational modification
antenatal diagnosis, 681–682	per cent HbS polymer, 668	glycated hemoglobins, 130–132
DNA diagnosis, 669–682	rate of sickling, 668	hemoglobin acetylation, 132–133
abnormal hemoglobins, 679–681	reticulocyte count, 665–666	M (met) hemoglobins, 597–599
HbC, 679	separation techniques, 658	clinical aspects, diagnosis, 599
HbE, 679	technique choice, 682	pathophysiology, 597–599
Hb O-Arab, 679	LCR and HbF, 641	iron oxidation, 598–599
	leg ulcers, 649	spectral characteristics, 598–599

MOI. <i>See</i> multiplicity of infection	sickle red cell adhesion, sickle cell disease, 146	gastrointestinal disturbances, 728
molecular control, hemoglobin switching, 88–90, 93	synthesis, 185–186	liver function, 728
gene competition, 92	tissue oxygen consumption, 190	other effects, 728
β-globin gene, regulatory elements, 89–90	tissue oxygen levels, 189–190	recommended dosing regimen, 728–729
β-globin locus control region, 90	vascular cell biology, 185–189	renal effects, 728
ε-globin gene, regulatory elements, 88–89	vascular tone, 191–192	skin rash, 728
globin gene splicing, 90–91	vasculature homeostatic functions, 191–192	deferasirox (ICL670, Exjade), 726–727
γ-globin gene, regulatory elements, 89	vasculature permeability	chemistry, pharmacology, 726–727
HbF control, adult, 92–93	apoptosis, 193–194	effects on heart, 727
molecular interactions, developmental	endothelial cell proliferation, migration, angiogenesis, 193	effects on iron balance, LIC, ferritin, 727
hematopoiesis, 14	leukocyte adhesion, 195–196	historical perspective, 726
morpholinos, morphants, 24	platelet adhesion, aggregation, 194–195	deferiprone, 721–724
mRNA, globin synthesis, Hb Bart's hydrops fetalis syndrome, 282	vascular smooth muscle cell proliferation, 194	chemistry, pharmacology, 721–722
causes, 281	NO. <i>See</i> nitric oxide	deferioximine, 725–726
severe fetal anemia, 282	NO bioavailability, vascular function, sickle cell disease, 148–149	clinical regimes assisted, 725
α <sup>0</sup> thalassemia defects, 281–282	non-deletion δβ thalassemia, 342	effect on heart, 726
multiplicity of infection (MOI)	non-deletion HPHF	effect on serum ferritin and liver iron, 725
human HSC transduction, 800	γ, β genes competition, 347	heart, 726
murine retroviral vectors, 792–795	γ genes promoters, mutations, 345	pharmacology, 725
mutations, 589–590	non-NO vasodilators, vascular function, sickle cell disease, 148–149	serum ferritin and liver iron, 725
distribution, 589–590	non-thalassemic fusion globins, 604	treatment safety, 726
rare, 599–604	NO resistance, intravascular hemolysis, 206–209	efficacy, 722–724
interesting α-globin gene variants, point mutations	NOS substrate bioavailability, arginaseemia limitations, intravascular hemolysis, 209	heart, 723–724
HbG-Philadelphia, 601–602	novel compound heterozygous conditions, 604	iron excretion, balance, 722
HbI, 602–603	novel treatment approaches	liver iron, 722–723
Hb Setif pseudosickling, hemoglobin oligomerization, 602	anti-adhesion therapy, sickle cell disease, 759–761	neutropenia, agranulocytosis, 724
hemoglobin Porto Alegre, 602	anti-inflammatory therapy, 762–763	recommended dosing, 724
interesting β-globin gene variants, point mutations, 600–601	ET-1, 762–763	serum ferritin, 722
Hb Costa Rica, 601	sulfasalazine, nuclear factor (NF)-κB, 762	unwanted effects, 724
hemoglobin G Couthatta, 600–601	anti-oxidant therapy targeting erythrocyte, 765–766	oral glutamine, 765
hemoglobin Vicksburg, 601	deferiprone, 765	oral N-acetyl-cysteine, 765–766
non-thalassemic fusion globins, 604	oral glutamine, 765	organ pathology, sickle cell disease, animal models, 230–232
N-terminal elongated globins, 600	oral N-acetyl-cysteine, 765–766	brain, 232
post-translational modifications, 599–600	anti-oxidant therapy targeting vasculature, 763–765	kidney, 230
acetylation, 600	Apo A-I mimetics, 764	liver, 231
deamidation, 599	NO, 763–764	lung, 232
Hb Raleigh, 600	statins, 764	microcirculation, 230–231
oxidation, 599–600	xanthine oxidase inhibitors, 764–765	pulmonary hypertension, 232
two mutation points in globin chain, 603	anti-thrombotic therapy	retina, 230
MWC/Perutz model, 102–104	sickle cell disease, 761–762	spleen, 232
myelodysplastic syndromes (MDS), ATMDs, 312–317	β-thalassemia, 761–762	osteonecrosis, 649
myelopoiesis, 8–9	erythrocyte dehydration inhibitors, 757–759	oxidation, 158–159, 166–167, 599–600
natural selection, 626–629	Gardos channel, 757–758	oxidative stress, sickle cell disease, 140–141
neonatal repopulating HSCs, 10	K-C1 transport inhibition by magnesium, 758–759	oxygen saturation measurements, P <sub>50</sub> , 662–663
neonates, ATRX syndrome, 304	sickle cell disease, 757	oxygen tension, red cell rheology, sickle cell disease, 139–140
NF-E2, related proteins, 73–74	β-thalassemia, 759	oxygen transport, 101–104
action mechanisms, 74	hemoglobin modifiers, 755–757	paladin, 34
Maf family, 73–74	sickle cell disease, 755–756	para-aortic splanchnopleura (PAS), 6
MARE elements, 73–74	β-thalassemia, 756–757	PAS. <i>See</i> para-aortic splanchnopleura
p45 family, 73	N-terminal elongated globins, 600	PcG. <i>See</i> polycomb group proteins
nitric oxide (NO), 763–764	number, chromosomal localization, 46–47	p45 family, NF-E2, related proteins, 73
biochemistry, 185–189	O <sub>2</sub> pressure, HbS, 109–110	phastCons score, 52
bioreactivity, 186	oral chelation therapy, 721–729	phosphoinositides, 163–164
export from erythrocytes, 189	deferasirox, unwanted effects/management, 727–729	phospholipid asymmetry loss, 162–163
genetics, 185–189	children, 728	phospholipid asymmetry maintenance, 162
hemoglobin, nitrite reductase activity, 187–189		phylogenetic footprints, 51
hemoglobin bioreactivity, 187–189		physical interactions definition, distant DNA elements, 65–66
hemoglobin-oxygen affinity, 189–190		placenta, 5
hypoxic vasodilation, 190–191		platelet adhesion, aggregation, vasculature permeability, NO, 194–195



polymerization kinetics, HbS, 111–112	thalassemia, 151	leg ulcers, 649
population dynamics, 633–635	treatment, 215–216	osteonecrosis, 649
population genetics, global health burden		painful episodes, 646
control and management issues, 634–635		priapism, 649
epidemiological transition, 633–635		pulmonary disease, 649–650
epistatic interactions between protective		renal disease, 649
polymorphisms, 631		stroke, 646–649
ethical and counseling issues, 634–635		sickle cell dehydration, pharmacology, 173
genetic services in developing countries, 635		sickle cell disease, 139–150, 692, 706, 757
HbAS, 629		acute chest syndrome, 695
HbC, 629		acute splenic sequestration, 694
HbE, 629–630		acute stroke, 694–695
HbS, 629		blood product choice, 692–693
hemoglobin disorders distribution, 625–626		clinical application, 694
hemoglobin disorders frequency, 625–626		episodic transfusions, indications, 694–697
malaria hypothesis, 626–629, 632		exchange transfusion, 693
natural selection, 626–629		hematopoietic stem cell transplantation,
population dynamics, 633–635		780–787
severe forms of hemoglobinopathy		current results, 780–784
α thalassemia, 630		donor hematopoiesis effect, sickle
β thalassemia, 630–631		vasoocclusion, 784
positioning effects, globin vector expression,		growth, development after, 785–786
804		non-myeloablative, 783–784
post translational modifications, 599–600		stable donor-host chimerism, 782–783
acetylation, 600		hypercoagulability, 150
deamidation, 599		leukocytes, vasoocclusion, 147
EKLF, 72		perioperative management, 695–696
GATA-1, related proteins, 68		priapism, 696–697
Hb Raleigh, 600		red cell rheology, 139–140
oxidation, 599–600		oxygen tension, 139–140
pregnancy, 698		sickle red cell heterogeneity, 140
HbF, 122		sickle erythrocyte adhesive interactions,
HbH disease, 279		pathophysiology, 146
α thalassemia, 274–275		sickle red cell adhesion, 142
priapism, 211–212, 649, 696–697		endothelial response, 146
primitive cells, embryonic globins expression, 26		mechanics, 142–146
primitive erythropoiesis, 24–25		adhesive bridging proteins, 144
protein and cellular based methods, 658–664		assay systems, 142
capillary electrophoresis, 660		endothelial adhesion molecules, 144–146
capillary IEF, 660		extracellular matrix adhesion molecules,
electrophoresis, 658–659		146
HbA <sub>2</sub> , 662		hydroxyurea, 146
HbF, 661–662		NO, 146
hemoglobin, functional properties, 662–663		red cell receptors, 143–144
hemoglobinopathies, clinical evaluation,		simple transfusion, 693
668–669		transfusion methods, 693
HPLC, 660		transient aplastic episode, 694
isoelectric focusing, 659–660		vascular biology factors, 140–142
mass spectrometry, 660–661		endothelial activation, 141–142
oxygen saturation measurements, P <sub>50</sub> , 662–663		oxidative stress, 140–141
red cell polymer formation detection, solutions		vascular function, 147–150
containing HbS, 663–664		NO bioavailability, 148–149
C <sub>SAT</sub> , 663–664		non-NO vasodilators, 148–149
plasma hemoglobin, 664		red cell rheology, vascular tone response,
solubility, 663		147–148
sample preservation, preparation, laboratory		vascular reactivity, 148–149
safety, 658		vasoconstrictors, altered vascular responses,
thalassemias, clinical evaluation, 668–669		149–150
protein conformation, HbF, 119		vasoocclusive pain episode, 696
proximal enhancers, human globin genes, 55–56		sickle cell disease models
pseudogenes, human globin genes, 48		animal models, transgenic mice, 227–232,
pulmonary disease, 649–650		801–802
pulmonary hypertension, 211–213, 698–699		erythrocytes, 229
children, 214–215		sickle transgenic mice, 227–229
diagnosis, 215–216		organ pathology, animal models, transgenic
patient prognosis, 213		mice, 230–232
	rare complications, HbH disease, 280	
	recombinant hemoglobins, 604	
	recurrent acute chest pain, 698–699	
	recurrent painful episodes, 699	
	recurrent splenic sequestration, 699	
	red blood cell characterization, 664–669	
	CBC, 664–668	
	automated methods, 665	
	cell heterogeneity measures, 666–667	
	globin chain synthesis, 667–668	
	hemoglobin S polymerization, 668	
	manual methods, 664	
	per cent HbS polymer, 668	
	rate of sickling, 668	
	reticulocyte count, 665–666	
	red cell indices	
	hematologic findings	
	Hb Bart’s hydrops fetalis syndrome, 282	
	HbH disease, 277	
	α thalassemia, 267–270	
	red cell polymer formation detection, solutions	
	containing HbS, 663–664	
	C <sub>SAT</sub> , 663–664	
	plasma hemoglobin, 664	
	solubility, 663	
	red cell receptors, sickle red cell adhesion,	
	143–144	
	red cell rheology	
	sickle cell disease, 139–140	
	oxygen tension, 139–140	
	sickle red cell heterogeneity, 140	
	thalassemia, 150–151	
	vascular tone response, 147–148	
	REDS signalling, 34	
	reduced HbA <sub>2</sub> , post-translational causes, HbA <sub>2</sub> ,	
	clinical aspects, 126	
	Regulatory Potential (RP) score, 52	
	renal disease, 649	
	RP score. <i>See</i> Regulatory Potential score	
	Runx1 haploinsufficiency, 17	
	sample preservation, preparation, laboratory	
	safety, 658	
	SCL. <i>See</i> stem cell leukemia	
	SCL transcription, 16	
	secondary territories, developmental	
	hematopoiesis	
	bone marrow, 6–7	
	liver, 6–7	
	separation techniques, 658	
	severe anemia episodes, HbH disease, 278	
	severe forms of hemoglobinopathy	
	SF. <i>See</i> steel factor	
	short chain fatty acids, hemoglobin switching,	
	93–94	
	sickle cell anemia, 645	
	bacteremia, 649	
	compound phenotypes, integrated measures,	
	651	
	genetic polymorphisms, disease severity	
	predictors, 645–651	
	G-6-PD deficiency, 650–651	
	hyperbilirubinemia, gallstones, 650	

sickle cell disease models ( <i>cont.</i> )	simple transfusion, 693	in-frame deletions, 252–255
brain, 232	skeletal abnormalities, ATRX syndrome, 305	mRNA translation initiation, 254–255
kidney, 230	sodium/hydrogen exchange, 165–167	nonsense mutations, 252–255
liver, 231	sodium permeability, cell sodium, 167	poly(A) addition signal, 252–254
lung, 232	sodium-potassium ATPase, 165–167	sickle cell disease
microcirculation, 230–231	spleen, intravascular hemolysis, 209–211	$\beta$ thalassemia, 644–645
pulmonary hypertension, 232	splicing, human globin genes, 47	unstable $\beta$ chain variants, 255–256
retina, 230	statins, 764	unusual types
spleen, 232	steel factor (SF), 16	ATMDS, 312–317
transgenic mice, 230–232	stem cell leukemia (SCL), 70	ATRX mutations in, 315–316
brain, 232	stress, oxidation, 158–159, 166–167	clinical features, 313
kidney, 230	stress erythropoiesis, 34–35	drug therapies, 316
liver, 231	stroke, 212, 646–649, 694–695, 697	$\alpha$ - to $\beta$ -globin chain synthesis ratio, 313
lung, 232	structural globin variants interaction, $\alpha$	$\alpha$ - to $\beta$ -globin mRNA ratio, 313
microcirculation, 230–231	thalassemia, 286	hemoglobin analysis, 314–315
pulmonary hypertension, 232	structure-function analysis, GATA-1, related	MDS pathobiology, 316
retina, 230	proteins, 68	molecular, cellular basis, 315
spleen, 232	sulfasalazine, nuclear factor (NF)- $\kappa$ B, 762	red cell indices, hematologic findings,
sickle cell disease phenotype, $\beta$ -globin gene	sulhemoglobinemia, 616–617	313–314
cluster haplotype effects, 643–644	clinical presentation, diagnosis, treatment,	sex imbalance, 316
sickle cell hemoglobin (HbS), 105–113	616–617	summary, 316–317
$\beta$ –93 cysteine, 110	definition, pathogenesis, 616	ATR-16 syndrome, 296–304
double nucleation theory, 111	T, B lymphoid lineage, mouse populations, 9	chromosomal imbalance, 301–303
HbS co-polymerization, 110–111	targeted mutagenesis, transcription factors,	genetic abnormalities definition, 299–301
HbS higher order aggregation, 106–108	66–67	mental retardation, 296
HbS polymer, 105–106	targeting endothelin-1 (ET-1), 762–763	summary, 303–304
HbS polymerization, red blood cells, 113	TCD. <i>See</i> abnormal transcranial Doppler	ATRX syndrome, 304–311
HbS polymer melting, 112–113	ultrasonography	associated phenotype, 308
HbS polymer rheology, 108	terminal erythroid maturation, platelet formation	ATMDS, 315–316
HbS thermodynamics, 108–109	GATA-1, related proteins, 67	ATRX, normal functional role, 310–311
heterogeneous nucleation, 112	TGF- $\beta$ superfamily, 14–16	ATRX gene, protein product, 307–308
homogeneous nucleation, 111–112	$\alpha^0$ thalassemia, 248–250	cardiac abnormalities, 305
O <sub>2</sub> pressure, 109–110	$\alpha$ 1 globin gene deletion, $\alpha$ 2 globin gene	clinical findings, 304–305
polymerization effectors, 109–110	inactivation, 250–251	disease gene identification, 306–307
polymerization kinetics, 111–112	$\alpha$ 2 globin gene deletion, $\alpha$ 1 globin promoter, 250	facial appearance, 305
sickle cell volume regulation pathology,	$\alpha$ thalassemia, 630, 671–673	gastro-intestinal abnormalities, 305
multi-track model, 172–174	deletion mutations by PCR diagnosis, 671–672	head circumference, brain size, 304–305
cation transport	diagnostic strategy, 671	hematologic findings, 305–306
other hemoglobinopathies, 174	$\zeta$ -globin regulatory element deletions, 251–252	mutations, functional consequences, 311
thalassemia, 174	HbA <sub>2</sub> clinical aspects, 127	neonates, 304
sickle cell dehydration, pharmacology, 173	molecular diagnosis, 256–257	phenotype relationship, 308–309
sickle erythrocyte adhesive interactions,	new transcription promoter, mutation, 256	skeletal abnormalities, 305
pathophysiology, 146	non-deletion types, 252	subject behavior, 305
sickle red cell adhesion, sickle cell disease,	physiology/clinical features, 266	summary, 311
142	$\alpha/\beta$ globin mRNA, 266–267	urogenital abnormalities, 305
endothelial response, 146	$\alpha$ globin structural variants interaction,	X-linked condition, 306
mechanics, 142–146	286–287	developmental abnormalities, 296
adhesive bridging proteins, 144	$\beta$ globin structural variants interaction,	$\beta$ thalassemia, 630–631, 640–641, 651–652,
assay systems, 142	287–288	673–679, 759
endothelial adhesion molecules, 144–146	globin synthesis ratios, 266–267	allele-specific oligonucleotide PCR, 673–674
extracellular matrix adhesion molecules,	Hb Constant Spring mutation, 275–276	alpha-hemoglobin stabilizing protein role,
146	hematologic findings, 267–270	644–645
hydroxyurea, 146	hematologic phenotype, $\beta$ globin variants,	bone disease, 652
NO, 146	288	cardiovascular disease, 652
red cell receptors, 143–144	hemoglobin analysis, 270–273	diagnostic strategy, 673
sickle red cell heterogeneity, 140	homozygotes, $\beta$ chain abnormalities, 288–289	gap-PCR, MLPA analysis, 677
signalling pathways, developmental	management, genetic counselling, 273–274	genetic polymorphisms, disease severity
hematopoiesis, 14–16	mild hemolytic anaemia, 275–276	predictors, 651–652
BMP-4, 16	pregnancy, 274–275	$\beta$ -globin gene haplotype analysis, 678–679
c-kit/SF signalling, 16	red cell indices, 267–270	hyperbilirubinemia, gallstones, 651
hedgehog signalling, 15	secondary effects, 266	iron loading, 651–652
TGF- $\beta$ superfamily, 14–16	structural globin variants interaction, 286	molecular basis
VEFG/Flk-1 axis, 16	point mutations by PCR diagnosis, 672–673	deletions restricted to $\beta$ globin gene, 331
visceral endoderm contact, 15	RNA splicing, mutations, 252–255	dominantly inherited, 323, 332
signal transduction molecules, knockout	chain termination mutants, 255–256	$\beta$ -globin chain reduction, 323
phenotypes, 32–33	frameshifts, 252–255	missense mutations, 332–335
silent cerebral infarcts, 698		dominant pathophysiology, 336

elongated/truncated variants, abnormal carboxy terminal ends, 335–336 intact codons, deletion or insertion, 335 nonsense mediated decay, 336 nonsense mutation, 335 premature termination, 335 mutations abnormal posttranscriptional modification, 330 premature translation termination, 330 mutations, RNA processing, 328–330 alternative splice sites, exons, 330 initiation codon, 330–331 splice site consensus sequence, 328 splice site junction, 328 non deletion forms, 323 nonsense mutation, 335 phenotype severity, 323 transcriptional mutants, 328 unusual causes, 337–338 β globin gene, somatic deletion, 337–338 trans-acting mutations, 337 transposable element insertion, 337 variants, 336–337 normal HbA <sub>2</sub> , 336–337 silent β, 337 unusually high HbA <sub>2</sub> , 337 mouse models, 801–802 oligonucleotide microarrays, 674 PCR methods, unknown mutations, 677–678 point mutations, other methods, 677 primer-specific amplification, 674–675 restriction enzyme PCR, 675–677 δβ thalassemia, 679 HPFH deletions, 344–345 GγAγ and δβ competition, 344 newly apposed enhancer sequences, 344–345 regulatory regions loss, 344 δ thalassemia, HbA <sub>2</sub> clinical aspects, 127 εγδβ thalassemia, 338 Gγ(Aγδβ)γ thalassemia, 342–343 γ thalassemia, HbF, 124 thalassemia major (Cooley's anemia), 705–706 beginning, 690–691 blood product choice, 690 frequency, amount, 691 hemoglobin level blood requirements, 689–690 physiological parameters, 689 partial exchange transfusion, 691–692 thalassemia major, 689 transfusion programs, 689 young blood cells, 691 thalassemia patient, bone marrow transplantation effect, 778–780 endocrine dysfunction, 780 hepatitis, 779–780 iron overload, 779 mixed chimeric state, 778 patient selection, 777–778 risk classification, 777–778 thalassemia recurrence, 778 thalassemia-related complications, 779 transplant-related complications, 778–779 thalassemias, 150–151 clinical evaluation, 668–669 embryonic hemoglobins, 130 hypercoagulation, 151 red cell rheology, 150–151 vascular pathobiology, 151 cardiac, arterial abnormalities, 151 pulmonary hypertension, 151 thalassemic mice, 225–227. <i>See also</i> animal models, transgenic mice α thalassemia-myelodysplastic syndromes (ATMDS), 312–317 ATRX mutations in, 315–316 clinical features, 313 drug therapies, 316 α- to β-globin chain synthesis ratio, 313 α- to β-globin mRNA ratio, 313 hemoglobin analysis, 314–315 MDS pathobiology, 316 molecular, cellular basis, 315 red cell indices, hematologic findings, 313–314 sex imbalance, 316 summary, 316–317 tissue, developmental specificity tissue oxygen consumption, NO, 190 tissue oxygen levels, NO, hemoglobin-oxygen affinity, 189–190 transcription factors developmental hematopoiesis, 16–17 CBF, 17 GATA-2, 16–17 Runx1 haploinsufficiency, 17 SCL, 16 erythroid EKLf, 72–73 chromatin structure remodelling, 72 post translational modifications, 72 EKLf, CACCC box-binding proteins, 70–73 β-globin gene expression, 70–71 β-globin switching, 71 GATA-1, related proteins, 67–70 GATA-1 interacting proteins, 68–69 GATA protein family, 67 human disease, 69–70, 75 post translational modifications, 68 structure-function analysis, 68 terminal erythroid maturation, platelet formation, 67 transcription repression, 68 general principles, 62–63 NF-E2, related proteins, 73–74 action mechanisms, 74 Maf family, 73–74 MARE elements, 73–74 p45 family, 73 SCL, 70 experimental approaches, 63–67 biochemical purification, 63–64 ChIP analysis, 64–65 chromatin immunoprecipitation, 64 erythroid differentiation, tissue culture models, 64 microarray analysis, 64–65 physical interactions definition, distant DNA elements, 65–66 targeted mutagenesis, 66–67 general principles, 62–63 transcription regulation, erythropoiesis, 35–36 transcription repression, GATA-1, related proteins, 68 transfusion methods, 693 transfusion therapy chronic transfusion therapy indications, 697–699 abnormal transcranial Doppler ultrasonography (TCD) other proposed indications, 699 pregnancy, 698 pulmonary hypertension, 698–699 recurrent acute chest pain, 698–699 recurrent painful episodes, 699 recurrent splenic sequestration, 699 silent cerebral infarcts, 698 stroke, 697 complications, 699–702 alloimmunization, 700–701 sickle cell disease, 700–701 thalassemia, 700 encephalopathy, 702 hypersplenism, 701–702 hypertension, 702 transfusion-transmitted infections, 701 other approaches, 699 other hemoglobinopathies, 699 sickle cell disease, 692 acute chest syndrome, 695 acute splenic sequestration, 694 acute stroke, 694–695 blood product choice, 692–693 clinical application, 694 episodic transfusions, indications, 694–697 exchange transfusion, 693 perioperative management, 695–696 priapism, 696–697 simple transfusion, 693 transfusion methods, 693 transient aplastic episode, 694 vasoocclusive pain episode, 696 thalassemia major (Cooley's anemia) beginning, 690–691 blood product choice, 690 frequency, amount, 691 hemoglobin level blood requirements, 689–690 physiological parameters, 689 partial exchange transfusion, 691–692 thalassemia major, 689 transfusion programs, 689 young blood cells, 691 transfusion-transmitted infections, 701 transient aplastic episode, 694 transport, other gases, hemoglobin, normal function, 104–105 trithorax group (trxG), 17–18 trxG. <i>See</i> trithorax group two mutation points in globin chain, 603 type I cytochrome b5 reductase deficiency, 609 type II cytochrome b5 reductase deficiency, 609–610 tyrosine c-kit receptor, 8  unstable hemoglobins. <i>See</i> hemoglobins, unstable upstream regulatory sequences, human globin genes, 53–55 urogenital abnormalities, ATRX syndrome, 305
--

vascular biology factors, sickle cell disease, 140–142	vascular reactivity, sickle cell disease, 148–149	VBIs. <i>See</i> ventral blood islands
endothelial activation, 141–142	vascular smooth muscle cell proliferation, 194	VEFG/Flk-1 axis, 16
oxidative stress, 140–141	vasculature permeability, NO	ventral blood islands (VBIs), 25
vascular function, sickle cell disease, 147–150	apoptosis, 193–194	viral vectors
NO bioavailability, 148–149	endothelial cell proliferation, migration, angiogenesis, 193	visceral endoderm contact, 15
non-NO vasodilators, 148–149	leukocyte adhesion, 195–196	
red cell rheology, vascular tone response, 147–148	platelet adhesion, aggregation, 194–195	xanthine oxidase inhibitors, 764–765
vascular reactivity, 148–149	vascular smooth muscle cell proliferation, 194	x-linked condition, ATRX syndrome, 306
vasoconstrictors, altered vascular responses, 149–150	vasoconstrictors, altered vascular responses, 149–150	
vascular pathobiology, thalassemia, 151	vasoocclusive pain episode, 696	yolk sac, 4–5
		zidovudine-treated patients, HbA <sub>2</sub> , clinical aspects, 129